Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.70 |
| ▸ | HTR1A | P08908 | 2/20 | 0.70 |
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 8/20 | 0.52 |
| ▸ | DRD3 | P35462 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4260687 | 0.99 | DRD2 (0.69) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL4258649 | 0.90 | DRD2 (0.72) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL4254837 | 0.89 | DRD2 (0.71) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL4249939 | 0.88 | DRD2 (0.74) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL4259307 | 0.88 | DRD2 (0.73) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL31038574 | 0.83 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL3408535 | 0.83 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL3404095 | 0.82 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL31038578 | 0.82 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL8160207 | 0.81 | DRD2 (0.80) | DRD2HTR1AHTR2AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207163-B2 | Compositions, synthesis, and methods of using piperazine based antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | DRD2 33/4885HTR1A 121/4885HTR2A 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.